did a another big order at 45 a few days ago
Jessica Amir: What are the avenues for growth?
Paul Anderson: The avenues for growth in this company are significant, and I think we find ourselves in a remarkable position. We have a first in class cellular therapy for the regeneration of human tendon tissue that we've partnered with Johnson & Johnson Innovation in a clinical study, which is designed to drive us through into the FDA process.
The opportunity with CelGro is enormous. We have a genuine platform technology that can be applied across several different tissue types, all of which have large unmet clinical needs. And for us, all the great work that we've done thus far in our clinical trials and validating this technology is really designed to drive these products into the US market, the FDA approval process, and we're really gearing ourselves up to do that with the support of some great clinicians, some very well designed clinical studies, and obviously some great collaborative relationships that we've formed to assist to drive us into this really important US-based market.
- Forums
- ASX - By Stock
- OCC
- FDA significance
FDA significance, page-7
-
- There are more pages in this discussion • 496 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OCC (ASX) to my watchlist
(20min delay)
|
|||||
Last
42.0¢ |
Change
-0.010(2.33%) |
Mkt cap ! $88.02M |
Open | High | Low | Value | Volume |
43.0¢ | 43.0¢ | 42.0¢ | $57.09K | 134.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 9415 | 42.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
42.5¢ | 17863 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 9415 | 0.420 |
3 | 13835 | 0.415 |
5 | 94649 | 0.410 |
2 | 26293 | 0.405 |
9 | 85050 | 0.400 |
Price($) | Vol. | No. |
---|---|---|
0.425 | 17863 | 1 |
0.430 | 16127 | 3 |
0.435 | 10000 | 1 |
0.440 | 6391 | 2 |
0.445 | 99431 | 2 |
Last trade - 13.39pm 27/09/2024 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |